Dose Enhancement of Vancomycin IN Everyday Patients

• Status: Unknown status
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Current Australian guidelines for vancomycin commonly underdoses individuals particularly in the first 48 hours.

The aim of the trial is to compare two dosing regimens; the current Australian guidelines versus a more appropriately modeled pharmacokinetic based regimen with the overall aim of developing a new vancomycin dosing strategy that will enable patients to have more individualised and therapeutically efficacious treatment.

The hypothesis is that dosing vancomycin according to a pharmacokinetically modeled regimen increases the likelihood of achieving therapeutic trough levels of vancomycin within the first 48 hours (or at steady state, whichever is sooner) compared to dosing vancomycin according to the current Antibiotic guidelines.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Canberra Hospital
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

• All patients in general wards requiring routine treatment with vancomycin

Exclusion Criteria:

• GFR < 30mL/min(as measured by Cockcroft Gault equation)

• Age < 16 yrs

• Weight > 200kg

• Patients dosing with Vancomycin other than BD according to national guidelines (ie continuous infusions, q6h etc)

• Vancomycin infused at a rate other than 500mL/min